Qubigen and the University of Adelaide Sign Master Agreement to Advance AI-based Drug Development

Qubigen is pleased to announce the signing of a Master Data Access Agreement with the University of Adelaide, formalizing a cooperative relationship to explore AI driven approaches to drug design using proprietary scientific data.

This agreement provides a legal and operational framework for structured, secure access to selected research datasets that will allow application of Qubigen’s Federated AI and molecular design platform. Under the agreement, Qubigen’s Federated AI will be able to draw insights from scientific data without moving or seeing the data. The intention is to advance University projects looking to develop therapeutic drugs for specific target proteins. This data will be used exclusively to train and validate proprietary AI models within a secure computing environment, which is a critical component of Qubigen’s privacy preserving platform architecture.

Advancing Predictive Molecular Design

Qubigen will apply its AI algorithms to real-world, domain-specific datasets to develop AI models for generating novel small molecule drug candidates, while ensuring the University of Adelaide’s data and intellectual property remain fully protected. In parallel, the University of Adelaide will advance translational research projects, leveraging their early-stage data and Qubigen’s AI outputs to inform ongoing research.

Two initial projects will be contemplated, one project with the Adelaide Drug Discovery Incubator (ADDI) and one project with the South Australian immunoGENomics Cancer Institute (SAiGENCI). This strategic partnership reinforces Qubigen’s commitment to collaborative AI research in drug design, securely unlocking value from underutilized data across academia and industry. Qubigen aims to accelerate the development of novel drugs without compromising on privacy or IP.

Looking Ahead

Qubigen looks forward to initiating its first project under this agreement and welcomes future opportunities to collaborate with academic institutions that share a vision for secure, data-driven innovation in life sciences.

Qubigen - accelerate drug design without exposing secrets

Whether you're advancing active programs, reviving dormant data, or starting from scratch, Qubigen’s secure AI platform and virtual screening capabilities can help you identify, optimize, and accelerate the path to promising lead drug candidates. Get in touch to explore how we can support your next discovery.

enquiries@qubigen.com